Skinbiotherap. Share News (SBTX)

SkinBioTherapeutics half-year revenue jumps on UK-based sales

(Alliance News) - SkinBioTherapeutics PLC on Friday said it saw its interim revenue soar on higher sales in the UK, as well as more returns across Europe, and affirmed that its full-year trading remains in line with guidance.

SkinBioTherapeutics announces research into wound healing bacterium

(Alliance News) - SkinBioTherapeutics PLC on Monday said that it has begun a new research and development project in partnership with the University of Manchester.

UK earnings, trading statements calendar - next 7 days

TRADING UPDATES: Avacta plans fundraise to fund clinical development

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

TRADING UPDATES: Windward extends LSEG pact; Vinanz eyes DTC trading

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

SkinBioTherapeutics reports positive interim acne study findings

(Sharecast News) - Life science company SkinBioTherapeutics reported encouraging interim findings from its ongoing AxisBiotix acne food supplement study featuring its lead formulation on Tuesday.

SkinBio's Dermatonics launches Once Heel Balm in Asia, ME and Africa

(Alliance News) - SkinBioTherapeutics PLC on Tuesday said its newly acquired Dermatonics will launch Pheet and Dermatonics Once Heel balm in Asia, the Middle East and Africa.

IN BRIEF: SkinBioTherapeutics up after successful year for Dermatonics

SkinBioTherapeutics PLC - Newcastle, England-based life science company focused on skin health - Provides a trading update for the recently acquired Dermatonics Ltd, a Cambridgeshire-based manufacturer of skincare products. In January, SkinBio completed its acquisition of Dermatonics for an initial payment of GBP1.7 million, alongside a GBP1.3 million earn-out over three years. Dermatonics's revenue was GBP1.9 million for the year ended January 31, up 2.2% from GBP1.8 million a year prior. Earnings before interest, tax, depreciation and amortisation were GBP422,000 for the 12 months, up 77% from GBP230,000 adjusted Ebitda last year. Adjustments were a GBP150,000 stock write-off and GBP123,000 bad debt in financial 2023. As of January 31, Dermatonics had a cash balance of GBP149,000, down from GBP213,000.

SkinBioTherapeutics finalises acquisition of Dermatronics

(Sharecast News) - SkinBioTherapeutics announced on Friday that it has finalised the acquisition of Dermatonics, known for its topical and dermatological products within the skincare and wound care sector.

IN BRIEF: SkinBioTherapeutics completes Dermatonics purchase

SkinBioTherapeutics PLC - Newcastle, England-based life science company focused on skin health - Completes the the acquisition of Dermatonics Ltd. On Thursday, it agreed to buy Dermatonics for GBP1.7 million initially, plus up to a GBP1.3 million earn-out over three years. St Ives, Cambridgeshire-based Dermatonics makes topical and dermatological products for skincare and woundcare, using natural ingredients wherever possible. It has annual earnings of GBP230,000 on GBP1.8 million in revenue.

IN BRIEF: SkinBioTherapeutics buys Dermatonics; in talks for 2nd deal

SkinBioTherapeutics PLC - Newcastle, England-based life science company focused on skin health - Agrees to acquire Dermatonics Ltd for GBP1.7 million initially, plus up to a GBP1.3 million earn-out over three years. St Ives, Cambridgeshire-based Dermatonics makes topical and dermatological products for skincare and woundcare, using natural ingredients wherever possible. It has annual earnings of GBP230,000 on GBP1.8 million in revenue. SkinBioTherapeutics says the acquisition will be financed with a GBP1.6 million drawdown from a new GBP5.0 million convertible bond issue.

SkinBioTherapeutics suffers acquisition delay but aims for early 2024

(Alliance News) - SkinBioTherapeutics PLC on Friday said it expects to complete an acquisition early in 2024, missing its year-end target.

UK shareholder meetings calendar - next 7 days

EARNINGS AND TRADING: Dispensa and SkinBioTherapeutics losses widen

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

TRADING UPDATES: SkinBio launches food supplement on Amazon

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: